If you have any questions, please contact AlphaScrip at 1-877-274-3244.
Are you enrolled in any state-, federal-, or government-funded medical health insurance or prescription benefit program (including, but not limited to, Medicare, Medicaid, Medigap, VA, TRICARE, DOD, or CHAMPUS)?
Are you a US resident and at least 18 years old?
*For eligible commercially insured patients. Maximum savings limit applies; patient out-of-pocket expense may vary.
Please see Program Terms, Conditions, and Eligibility Criteria, which include additional exclusions.
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF ROXYBOND
Because the use of ROXYBOND exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions.
Life-Threatening Respiratory DepressionSerious, life-threatening, or fatal respiratory depression may occur with use of ROXYBOND, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ROXYBOND are essential.
Accidental IngestionAccidental ingestion of even one dose of ROXYBOND, especially by children, can result in a fatal overdose of oxycodone.
Risks From Concomitant Use With Benzodiazepines Or Other CNS DepressantsConcomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of ROXYBOND and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
Neonatal Opioid Withdrawal Syndrome (NOWS)If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.
Cytochrome P450 3A4 InteractionThe concomitant use of ROXYBOND with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Regularly evaluate patients receiving ROXYBOND and any CYP3A4 inhibitor or inducer.
These are not all the possible side effects of ROXYBOND. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov
Please see additional Important Safety Information, and full Prescribing Information, including BOXED WARNINGS and Medication Guide at www.ProtegaPharma.com prior to taking ROXYBOND. Speak with your healthcare provider if you have additional questions about ROXYBOND.